AEMPS authorizes the initiation of the clinical trial of AP-2, Molefy Pharma’s therapeutic candidate for ALS
AEMPS authorizes the initiation of the clinical trial of AP-2, Molefy Pharma’s therapeutic candidate for ALS • The AEMPS authorizes the initiation of the Phase I clinical trial of AP-2, which will begin in April at Hospital Universitario de La Princesa with 70 healthy volunteers • AP-2, developed by Molefy Pharma based on CSIC research, targets the TDP-43 […]
Molefy Pharma receives Orphan Drug Designation (ODD) from the European Union for its AP-2 candidate in the treatment of amyotrophic lateral sclerosis (ALS)
The European Medicines Agency (EMA) has granted Molefy Pharma the Orphan Drug Designation (ODD) for its candidate AP-2, an innovative therapy developed for the treatment of amyotrophic lateral sclerosis (ALS). This designation is awarded to medicines with the potential to treat rare and severe diseases in the European Union, when they offer a significant benefit […]